Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 7Prostatic Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Melanoma 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Ovarian Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Solid Tumor 1Sarcoma, Synovial 1

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × tremelimumab × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡